Antimicrobial Photodynamic Therapy for Hospital-Acquired Infections
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a single-center, non-blinded, prospective, pilot study enrolling patients admitted to the critical care unit at Royal Columbian Hospital. This study investigates the effects of universal nasal decolonization using antimicrobial photodynamic therapy (aPDT) on the prevention of hospital-acquired pneumonia (HAP), ventilator-acquired pneumonia (VAP), and hospital-acquired bloodstream infection (BSI) in this patient population.Main Objectives include:* To determine whether a large, multi-center RCT of this protocol is feasible* To determine baseline rates of VAP, HAP, and ICU-acquired BSI* To gather preliminary efficacy data regarding VAP, HAP, and ICU-acquired BSI prevention using universal aPDT nasal decolonization* To gather preliminary microbiological data on the effect of universal aPDT procedures on nasal carriage of various microoganisms in ICU patients.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
Is antimicrobial photodynamic therapy (aPDT) safe for humans?
How is antimicrobial photodynamic therapy different from other treatments for hospital-acquired infections?
Antimicrobial photodynamic therapy (aPDT) is unique because it uses light to activate a special compound that produces a form of oxygen toxic to bacteria, making it effective even against antibiotic-resistant strains. Unlike traditional antibiotics, aPDT does not contribute to the development of resistance and can be combined with antibiotics or antifungals for enhanced effectiveness.12467
What data supports the effectiveness of the treatment Antimicrobial photodynamic therapy (aPDT) for hospital-acquired infections?
Research shows that antimicrobial photodynamic therapy (aPDT) can effectively reduce bacterial infections, including those caused by antibiotic-resistant bacteria, by using light and a special dye to kill germs. Studies have found that aPDT can be particularly useful for treating skin and soft tissue infections, and it works well even when combined with antibiotics or antifungal drugs to enhance its effectiveness.12689
Who Is on the Research Team?
Steven Reynolds
Principal Investigator
Fraser Health Authority
Are You a Good Fit for This Trial?
This trial is for patients in the critical care unit at Royal Columbian Hospital who may be at risk of hospital-acquired pneumonia or bloodstream infections. The study aims to include those who could benefit from nasal decolonization to prevent these infections.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Control Period
The first two months will constitute the control period before the aPDT intervention is introduced. No nasal decolonization procedures will take place at this time.
Intervention Period
Nasal decolonization procedures will be administered every other day. Nasal swabs will be collected every four days to assess microbiology.
Follow-up
Participants are monitored for safety and effectiveness after treatment, including a nasal swab collected 4-days post-ICU discharge if still hospitalized.
What Are the Treatments Tested in This Trial?
Interventions
- Antimicrobial photodynamic therapy (aPDT)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Fraser Health
Lead Sponsor
Royal Columbian Hospital Foundation
Collaborator
Ondine Biomedical Inc.
Industry Sponsor
Royal Columbian Hospital Foundation
Collaborator